Diplomat Pharmacy Inc (NYSE:DPLO) traded down 5.1% during trading on Thursday . The stock traded as low as $14.60 and last traded at $14.92. 917,733 shares traded hands during trading, a decline of 7% from the average session volume of 985,537 shares. The stock had previously closed at $15.72.

Several equities research analysts recently commented on the company. Robert W. Baird raised Diplomat Pharmacy from an “underperform” rating to a “neutral” rating and increased their price objective for the company from $10.00 to $15.00 in a research report on Friday. ValuEngine cut Diplomat Pharmacy from a “hold” rating to a “sell” rating in a research report on Wednesday, September 12th. Zacks Investment Research raised Diplomat Pharmacy from a “sell” rating to a “hold” rating in a research report on Tuesday, November 6th. Wells Fargo & Co dropped their price objective on Diplomat Pharmacy from $23.00 to $16.00 and set a “market perform” rating on the stock in a research report on Thursday, November 8th. Finally, Morgan Stanley dropped their price objective on Diplomat Pharmacy from $20.00 to $18.00 and set an “equal weight” rating on the stock in a research report on Monday. Two research analysts have rated the stock with a sell rating, five have issued a hold rating and six have assigned a buy rating to the company. Diplomat Pharmacy currently has a consensus rating of “Hold” and an average target price of $24.70.

The stock has a market capitalization of $1.17 billion, a PE ratio of 17.76 and a beta of 0.88. The company has a quick ratio of 0.66, a current ratio of 0.95 and a debt-to-equity ratio of 0.58.

Diplomat Pharmacy (NYSE:DPLO) last announced its earnings results on Tuesday, November 6th. The company reported $0.01 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.22 by ($0.21). The firm had revenue of $1.37 billion during the quarter, compared to analysts’ expectations of $1.42 billion. Diplomat Pharmacy had a return on equity of 5.31% and a net margin of 0.04%. The company’s revenue for the quarter was up 22.0% on a year-over-year basis. During the same period in the previous year, the business posted $0.01 earnings per share. Analysts anticipate that Diplomat Pharmacy Inc will post 0.79 EPS for the current fiscal year.

In other news, Director Philip R. Hagerman sold 209,367 shares of the firm’s stock in a transaction dated Thursday, September 13th. The stock was sold at an average price of $19.07, for a total value of $3,992,628.69. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director Philip R. Hagerman sold 57,500 shares of the firm’s stock in a transaction dated Tuesday, September 11th. The stock was sold at an average price of $19.21, for a total value of $1,104,575.00. The disclosure for this sale can be found here. Company insiders own 24.70% of the company’s stock.

Hedge funds and other institutional investors have recently bought and sold shares of the company. Capital International Investors bought a new stake in Diplomat Pharmacy during the 3rd quarter valued at approximately $99,092,000. FMR LLC raised its stake in Diplomat Pharmacy by 154.4% during the 2nd quarter. FMR LLC now owns 2,798,440 shares of the company’s stock valued at $71,528,000 after purchasing an additional 1,698,341 shares during the period. Frontier Capital Management Co. LLC raised its stake in Diplomat Pharmacy by 84.1% during the 3rd quarter. Frontier Capital Management Co. LLC now owns 3,535,217 shares of the company’s stock valued at $68,619,000 after purchasing an additional 1,614,645 shares during the period. Janus Henderson Group PLC raised its stake in Diplomat Pharmacy by 30.7% during the 2nd quarter. Janus Henderson Group PLC now owns 5,385,168 shares of the company’s stock valued at $137,645,000 after purchasing an additional 1,265,271 shares during the period. Finally, Victory Capital Management Inc. raised its stake in Diplomat Pharmacy by 17,568.5% during the 2nd quarter. Victory Capital Management Inc. now owns 1,239,442 shares of the company’s stock valued at $31,679,000 after purchasing an additional 1,232,427 shares during the period. 85.24% of the stock is currently owned by hedge funds and other institutional investors.

TRADEMARK VIOLATION WARNING: This article was first reported by Watch List News and is the sole property of of Watch List News. If you are reading this article on another publication, it was illegally copied and reposted in violation of international copyright and trademark legislation. The original version of this article can be read at https://www.watchlistnews.com/diplomat-pharmacy-dplo-shares-down-5-1/2667599.html.

Diplomat Pharmacy Company Profile (NYSE:DPLO)

Diplomat Pharmacy, Inc operates as an independent specialty pharmacy in the United States. The company stocks, dispenses, and distributes prescriptions for various biotechnology and specialty pharmaceutical manufacturers. It also provides specialty infusion pharmacy, patient care coordination, clinical, compliance and persistency program, patient financial assistance, specialty pharmacy training/consulting, benefits investigation, prior authorization, risk evaluation and medication strategy, retail specialty, and hub services, as well as clinical and administrative support services to hospitals and health systems.

Read More: What is the 52-week high/low?

Receive News & Ratings for Diplomat Pharmacy Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Diplomat Pharmacy and related companies with MarketBeat.com's FREE daily email newsletter.